Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma
NCT02478164
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
17
Enrollment
OTHER
Sponsor class
Conditions
Glioblastoma
Interventions
DRUG:
Ponatinib
Sponsor
Dana-Farber Cancer Institute